Saffron extract in the treatment of mild to moderate Alzheimer’s disease: A double blind randomized controlled trial.

Tehran University of Medical Sciences0 个研究点目标入组 50 人开始时间: 待定最近更新: 2018年2月22日

试验速览

暂无简介。

•Inclusion Criteria:
•A diagnosis of probable Alzheimer’s disease according to the criteria of National Institute of Neurological and Communicative Disorders and Stroke and Alzheimer’s Disease and Related Disorders Association (NINCDS/ADRDA); Presence of mild to moderate dementia [score of = 12 on the cognitive subscale of Alzheimer’s Disease Assessment Scale (ADAS-cog) and = 2 on Clinical Dementia Rating Scale (CDR)].

•Concomitant diseases such as hypertension, congestive heart failure, non-insulin dependent diabetes mellitus and hypothyroidism; Patients with evidence of other neurodegenerative disorders; Any cardiovascular disease likely to prevent completion of the study; Clinically significant psychiatric diseases; Urinary outflow obstruction; Active peptic ulcer; Any history of epilepsy; Significant drug or alcohol misuse; Drugs with anticholinergic effects or cholinomimetic effects.

发起方